Alveolar macrophages from nonatopic donors were passively sensitized with allergenspecific IgE antibody from the serum of asthmatic patients. A selective release of 4-8% of the lysosomal beta-glucuronidase of these cells occurred within 30 min of contact with the related allergen or with anti-human IgE antibody, in the absence of any mast or basophil cells. The cell reactivity was dependent on the interaction of macrophages with IgE, as shown by the disappearance of the allergen-induced enzyme release after heating or IgEimmune adsorption of the sensitizing serum, but not after IgG-adsorption. Alveolar macrophages from asthmatic patients behaved similarly to passively sensitized normal macrophages. Contact with the related allergen or with anti-IgE antibody induced the same percentage of enzyme release, demonstrating that these cells possess allergen-specific IgE bound on their surface. 18% of them formed rosettes with anti-IgE-coated sheep erythrocytes, and 15-22% with allergen-coated erythrocytes, but lost this property after preincubation with the specific allergen. The presence of IgE-specific receptors on the macrophage surface was demonstrated both at the ultrastructural level with immunoperoxidase labeling, and at low magnification by the formation of 15-18% rosettes with human IgE-coated erythrocytes. The formation of such rosettes was inhibited after incubation of alveolar phagocytes with aggregated myeloma IgE. On the basis of these observations, the participation of the alveolar macrophages in IgE-mediated pulmonary hypersensitivity must be considered. 
The cell reactivity was dependent on the interaction of macrophages with IgE, as shown by the disappearance of the allergen-induced enzyme release after heating or IgE-immune adsorption of the sensitizing serum, but not after IgG-adsorption. Alveolar macrophages from asthmatic patients behaved similarly to passively sensitized normal macrophages. Contact with the related allergen or with anti-IgE antibody induced the same percentage of enzyme release, demonstrating that these cells possess allergen-specific IgE bound on their surface. 18% of them formed rosettes with anti-IgE-coated sheep erythrocytes, and 15-22% with allergen-coated erythrocytes, but lost this property after preincubation with the specific allergen. The presence of IgE-specific receptors on the macrophage surface was demonstrated both at the ultrastructural level with immunoperoxidase labeling, and at low magnification by the formation of 15-18% rosettes with human IgE-coated erythrocytes. The formation of such rosettes was inhibited after incubation of alveolar phagocytes with aggregated myeloma IgE. On
INTRODUCTION
The first evidence of a direct interaction of IgE antibody with the macrophage was obtained when studying an antibody-dependent cell-mediated cytotoxicity against larvae of Schistosoma mansoni (1-3) and Dipetalonema viteae (4) . These experiments showed that such an interaction induced the activation of normal mononuclear phagocytes from man and animals into cytotoxic effector cells. The freshly isolated (2 h) alveolar macrophages from asthmatic subjects were immediately triggered, directly in the petri dishes, by 10 Ml anti-IgE serum/ml, or by the allergen(s) responsible for the observed pathology. As (Fig. 1) . Unrelated allergens had no effect on IgE-or allergic serum-sensitized macrophages. Extracellular enzyme was produced by a secretory process, and was not the consequence of cell death or lysis, as judged by the absence of LDH in supernatants. The involvement of IgE antibody in the cell triggering by asthmatic sera was evidenced by the disappearance of significant enzyme exocytosis with allergens after specific IgE depletion, either by heating or by IgE adsorption of the sera. IgG adsorption had no inhibitory effect on the cell stimulation induced by specific allergens (Table II).
Allergenic stimulation of macrophages from asthmatic donors. Incubation of alveolar macrophages from asthmatic patients with anti-IgE or with allergens related to the patient sensitivity induced enzyme release without in vitro presensitization of the cells (Table III). Macrophages from normal individuals also showed a limited, but significant enzyme release with anti-IgE treatment. Allergens, however, had no triggering action on these normal cells. The allergen concentration uniformly used with all three preparations was 100 ng dry wt/ml final culture medium. With D. pteronyssinus, maximal enzyme release was obtained between 100 and 500 ng dry wt/ml, the shape of the dose-response curve being very similar to that ob- (Fig. 2) . However, no histamine could be demonstrated sented a high histamine release with the ionophore in the macrophage supernatants or in total cell lysates, A23187. ormal human macrophages, after overnight culture, were first incubated for 30 min in native or treated serum from asthmatic patients. After washing, the cells were incubated for a further 30-min period in heat-inactivated goat serum anti-human IgE (10 s1/ml HBSS), or in 100 ng specific allergen, or in HBSS alone. #-Glucuronidase release is expressed as nanomoles of hydrolysed substrate per 106 cells per hour (three experiments in triplicate). I Unadsorbed sera: 8.6 mg IgG/ml and 4.6 ,g IgE (2,000 IU)/ml. § Comparison with untreated serum: P < 0.001.
1" Solid-phase adsorbed sera: <0.025 jg IgE (<10 IU)/ml.
T Solid-phase adsorbed sera: 0.4 mg IgG/ml. 224 Joseph, Tonnel, Torpier, Capron, Arnoux, and Benveniste Electron microscopic observation of membrane IgE. IgE-specific peroxidase labeling of alveolar macrophages was obtained with both atopic and nonatopic cells as soon as isolated from the bronchoalveolar lavage in two reproducible experiments (Fig. 3) . With nonatopic macrophages, the IgE label was more diffuse and uniformly spread on the cell surface, whereas on macrophages from asthmatic patients the peroxidase activity was mainly localized on the cell processes. Anti-IgE and allergen-specific rosettes. The percentages of human alveolar macrophages forming rosettes with SRBC, anti-IgE-SRBC, and allergen-coated SRBC were compared in 10 controls and 11 asthmatic patients (Fig. 4) . While the mean percentage of rosette-forming macrophages with SRBC was the same in both groups, the number of anti-IgE-rosettes was increased threefold in asthmatic patients when compared with control alveolar macrophages.
In eight patients suffering from mite allergic asthma, the percentage of DP-SRBC rosettes was 19.7±1.2%. For the patients with GP allergy or A. fumigatus sensitivity, it was 15.5 and 22.2% for GP-SRBC and Asp-SRBC rosettes, respectively.
Rosette inhibition after incubation with IgE or allergen. In two asthmatic patients, a prior incubation of the alveolar macrophages with aggregated IgE induced a 50% reduction of the IgE-rosettes, whereas pretreatment with soluble allergens (5 Atg/ml), at 40C to avoid cell triggering, was also followed by an inhibition of allergen-specific rosettes (Fig. 5) . Similarly, pretreatment of macrophages from asthmatic patients with anti-IgE antibody at 40C completely inhibited the allergen-specific rosettes (96.7%) whereas anti-IgG pretreatment had no significant effect (16.7% inhibition of allergen-rosettes). Finally, an incubation with aggregated IgE induced no change in the number of anti-IgE rosettes with macrophages from asthmatic patients but a significant increase (300%) with normal cells.
DISCUSSION
In this study, we provide evidence that IgE antibody is capable of stimulating alveolar macrophages when asthmatic patient sera are used for the passive sensitization of normal cells, leading to a metabolic burst not only with anti-IgE as the triggering signal, but also with specific allergens. These results extend to 45 patients the previously reported observation (11) of the binding of allergen-specific IgE to the macrophage surface, subsequently triggered to selectively secrete lysosomal enzymes by a contact with allergen or antiIgE antibody. They also confirm the close relationship between the specificity of the triggering allergens and that of the IgE antibody, assayed by RAST, present in the sensitizing sera.
The crucial point for the interpretation of these results is, however, the possible presence and participation of mast or basophiloid cells in the process described here. Alveolar cells were collected after discarding the contaminant bronchial cells of the first 50 ml of the lavage. The morphological determination of cells, after Giemsa and toluidine blue staining, showed very low level of mast cell contamination in the crude populations, and, on the very rare occasions when some were visible, they were no longer present after the 2-h adherence stage. Furthermore, the absence of any histamine release during IgE-anti-IgE triggering of the cells, when significant enzyme release was measured, makes the participation of this cell type in the observed effect unlikely.
The molecular form of the IgE involved was not investigated here. However, monomeric as well as polymeric IgE were both demonstrated to bind to rat macrophages at 37°C, even if dimers and higher aggregates showed a better affinity than monomers (7) . In the present data, the possible participation of IgE immune complexes in the sera from asthmatic patients cannot be ruled out nor their possible spontaneous aggregation by the freezing conditions of storage. These points will be considered in the near future.
The participation of allergen-specific IgG in the passive sensitization of normal macrophages is doubtful, since the cell reactivity to the allergens was unchanged after the immune adsorption of IgG, whereas heating the sensitizing sera suppressed it. Furthermore, the time course of the process (30 min) makes a major role for IgG unlikely, since, as was shown with rat peritoneal macrophages, the IgG-anti-IgG triggering requires at least 6 h contact to reach the level of cell sensitization obtained within 30 min in the IgEanti-IgE procedure (19) . In fact, with passively sensitized alveolar macrophages, a 30-min incubation with anti-IgG did not induce a significantly higher level of enzyme release than incubation with control medium (Fig. 1) . The short duration of the incubation also accounts for the apparently low level of enzyme release, comprised between 4 and 10% of the total f3-glucuronidase content. The anti-IgE or the allergeninduced release could be increased by a longer incubation, but it was accompanied by a concomitant increase of the intracellular synthesis of the enzyme. The direct demonstration of an IgE antibody involvement in the allergen-induced enzyme release by macrophages from asthmatic patients is not given in the experiments reported here, as it is for passively sensitized normal macrophages. However, the time course of the fl-glucuronidase release in the presence of the specific allergens is very similar to that observed with anti-IgE, and its level significantly higher than after treatment by anti-IgG serum. The inhibition of allergen-specific rosettes, not only by preincubation with the related allergen but also by anti-IgE pretreatment, provides evidence that IgE antibody is the main isotype participating in the cell-triggering process with allergens. Experiments in progress on fractionated macrophage populations will give indications on the precise involvement of each immunoglobulin class in this mechanism.
In response to different stimulations, alveolar macrophages produce a large variety of mediators, such as hydrolytic enzymes (23) (24) (25) (26) , superoxide anion (11), platelet-activating factor (PAF-acether) (27) , slow-reacting substances (SRS) (28) and other arachidonic acid metabolites (29) (30) (31) . In this work, the choice of only lysosomal enzyme release as a parameter of cell stimulation was inspired by its practicality in a large screening study. Nevertheless, it allowed the demonstration of a significant difference in the behavior of alveolar macrophages from normal vs. asthmatic donors during the interaction of IgE antibody with the specific allergens. However, the release of this enzyme does not give information on the pathogenic role of the alveolar macrophage stimulation in the onset of bronchoconstriction. On the one hand, SRS from alveolar macrophages might intervene in this process. On the other hand, the bronchomotor action of PAFacether is well documented (32) . PAF-acether release by alveolar macrophages from asthmatic patients was observed in the stimulation process described here (Arnoux et al., submitted for publication). Investigations on the production of the other mediators cited above in the same pathological situation will provide new information on their role in regulating the functions of other cells (33, 34) , in increasing the cytotoxic properties of the pulmonary phagocytes, as well as in participating in the inflammatory reactions and tissue damage of the lung pathology.
Together with the IgE-dependent mechanism of specific killing by mononuclear phagocytes of at least two different metazoan parasite larvae (1-4) the interaction reported here between IgE antibody and alveolar macrophages opens an original approach to the triggering processes of this type of phagocytes. It gives indications of a new role for this immunoglobulin class, up till now restricted to anaphylactic functions at the basophil or mast cell level. Finally, besides the role of mast cells in the bronchial submucosa, the participation of the alveolar macrophage in the respiratory allergy must therefore be taken into account for full description of the lung hypersensitivity.
